EMULSIFIERS FOR COSMETICS

Antares Vitamin E TPGS has an array of applications in Cosmetic and Personal Care formulations. Not only has it been widely used in drugs to improve absorption and bioavailability, but it also works as an emulsifier/co-emulsifier for lipophilic actives or ingredients while simultaneously providing a water-soluble source of natural vitamin E. The science of vitamin E TPGS has been extensively studied and reported worldwide, showing/proving it to be one of the best and safest options for emulsifiers in skincare and other personal care products.

Common Uses in Personal Care & Cosmetics:

PERSONAL CARE PRODUCTS - Solubilizer for active ingredients

  • Eye drops

  • Nasal sprays

  • Mouth Rinses

  • Lip Balms

  • Syrups

COSMETICS - Topical vitamin E and solubilizer for active ingredients

  • Creams

  • Lotions

Formulating Advantages of Antares Vitamin E TPGS:

Antares manufactures Antares Vitamin E TPGS, a water-soluble form of vitamin E that can be used to improve absorption, bioavailability, and stability of substances malabsorbed by the body. Our customers benefit from working with a company based in the United States, receiving competitive pricing at smaller quantities alongside exceptional customer service. Here are some advantages of our product:

  • Available in multiple grades including NF, FG, and non-GMO Sunflower TPGS™ (NF and FG)

  • Long history (over 50 years) of safe use

  • Readily mixes with water, lipids, oils, and poorly-soluble ingredients

  • Readily forms emulsions of lipids and oils

  • Ethanol free

  • Hypoallergenic

  • Non-Irritating

  • Listed as Tocophersolan by the International Nomenclature of Cosmetic Ingredients (INCI)

 

If you need additional assistance regarding the use of Antares Vitamin E TPGS in your specific application, please contact us. For basic handling and use guidelines for Antares Vitamin E TPGS, see How To Use TPGS. Download Safety Data Sheet, Product Data Sheet and additional product documentation from our Documentation page.  

Selected References:

  1. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008 Jun;10(2):229-41.

  2. Aydemir O, Celebi S, Yilmaz T, Yekeler H, Kükner AS. Protective effects of vitamin E forms (alpha-tocopherol, gamma-tocopherol and d-alpha-tocopherol polyethylene glycol 1000 succinate) on retinal edema during ischemia-reperfusion injury in the guinea pig retina. Int Ophthalmol. 2004 Oct-Dec;25(5-6):283-9.

  3. Le Bourlais CA, Chevanne F, Turlin B, Acar L, Zia H, Sado PA, Needham TE, Leverge R. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study. J Microencapsul. 1997 Jul-Aug;14(4):457-67.

  4. Aggarwal N, Goindi S, Mehta SD. Preparation and evaluation of dermal delivery system of griseofulvin containing vitamin E-TPGS as penetration enhancer. AAPS Pharm Sci Tech. 2012;13(1):67–74.

  5. Telò I, Favero ED, Cantù L, et al. Gel-like TPGS-Based Microemulsions for Imiquimod Dermal Delivery: Role of Mesostructure on the Uptake and Distribution into the Skin. Mol Pharm. 2017;14(10):3281–3289.

  6. Benigni M, Pescina S, Grimaudo MA, Padula C, Santi P, Nicoli S. Development of microemulsions of suitable viscosity for cyclosporine skin delivery. Int J Pharm. 2018;545(1-2):197–205.

  7. Boakye CHA, Patel K, Doddapaneni R, et al. Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids Surf B Biointerfaces. 2016;143:156–167.

  8. Ghosh I, Michniak-Kohn B. A comparative study of vitamin E TPGS/HPMC supersaturated system and other solubilizer/polymer combinations to enhance the permeability of a poorly soluble drug through the skin. Drug Dev Ind Pharm. 2012; 38(11): 1408-16.

  9. Telò I, Favero ED, Cantù L, et al. Gel-like TPGS-Based Microemulsions for Imiquimod Dermal Delivery: Role of Mesostructure on the Uptake and Distribution into the Skin. Mol Pharm. 2017;14(10):3281–3289.

  10. Kaur L, Jain SK, Singh K. Vitamin E TPGS based nanogel for the skin targeting of high molecular weight anti-fungal drug: development and in vitro and in vivo assessment. RSC Adv. 2015; 5: 53671-86. (edited)